ZA201405070B - 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors - Google Patents

1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors

Info

Publication number
ZA201405070B
ZA201405070B ZA2014/05070A ZA201405070A ZA201405070B ZA 201405070 B ZA201405070 B ZA 201405070B ZA 2014/05070 A ZA2014/05070 A ZA 2014/05070A ZA 201405070 A ZA201405070 A ZA 201405070A ZA 201405070 B ZA201405070 B ZA 201405070B
Authority
ZA
South Africa
Prior art keywords
pyrrolo
kinase inhibitors
pyridine derivatives
pyridine
derivatives
Prior art date
Application number
ZA2014/05070A
Other languages
English (en)
Inventor
Emma Jayne Stefaniak
Stuart Christopher Ray
Christopher John Graham
Stephen Stokes
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Publication of ZA201405070B publication Critical patent/ZA201405070B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2014/05070A 2012-01-30 2014-07-11 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors ZA201405070B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1201566.5A GB201201566D0 (en) 2012-01-30 2012-01-30 New chemical compounds
PCT/GB2013/050212 WO2013114113A1 (en) 2012-01-30 2013-01-30 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors

Publications (1)

Publication Number Publication Date
ZA201405070B true ZA201405070B (en) 2016-03-30

Family

ID=45876325

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/05070A ZA201405070B (en) 2012-01-30 2014-07-11 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors

Country Status (21)

Country Link
US (3) US10000481B2 (en:Method)
EP (1) EP2809670B1 (en:Method)
JP (1) JP6199316B2 (en:Method)
CN (4) CN106866658B (en:Method)
AU (1) AU2013213954B2 (en:Method)
BR (1) BR112014018795B1 (en:Method)
CA (1) CA2862940C (en:Method)
DK (1) DK2809670T3 (en:Method)
EA (1) EA026657B1 (en:Method)
ES (1) ES2637340T3 (en:Method)
GB (1) GB201201566D0 (en:Method)
HK (1) HK1200447A1 (en:Method)
HU (1) HUE035332T2 (en:Method)
IL (1) IL233595B (en:Method)
IN (1) IN2014DN06104A (en:Method)
MX (1) MX352927B (en:Method)
NZ (1) NZ627361A (en:Method)
PL (1) PL2809670T3 (en:Method)
PT (1) PT2809670T (en:Method)
WO (1) WO2013114113A1 (en:Method)
ZA (1) ZA201405070B (en:Method)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
CA2871436C (en) * 2012-04-23 2020-07-28 Genentech, Inc. Intermediates and processes for preparing compounds for use as chk1 inhibitors
WO2015027092A1 (en) 2013-08-22 2015-02-26 Genentech, Inc. Process for preparing a compound
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
US10032914B2 (en) * 2015-10-20 2018-07-24 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device and manufacturing method thereof
PT3269370T (pt) 2016-02-23 2020-03-05 Taiho Pharmaceutical Co Ltd Novo composto de pirimidina condensada ou sal do mesmo
AU2018322286B2 (en) 2017-08-21 2022-03-10 Taiho Pharmaceutical Co., Ltd. Fusion protein of DCTN1 protein with RET protein
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病況的化合物及組合物
CN111518096B (zh) 2019-02-02 2022-02-11 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
EP4007757A4 (en) 2019-08-01 2023-07-19 Integral Biosciences Pvt. Ltd. HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS AND THEIR USES
IT202000005527A1 (it) * 2020-03-16 2021-09-16 Univ Degli Studi Di Trento Trattamento terapeutico di cromatinopatie
JP2023540673A (ja) 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
TW202216685A (zh) * 2020-07-15 2022-05-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
JP2023540674A (ja) * 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
TW202235073A (zh) 2021-01-08 2022-09-16 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
CN118613473A (zh) * 2022-01-12 2024-09-06 艾福姆德尤股份有限公司 用于治疗与sting活性相关的病症的化合物和组合物
CN116554170A (zh) * 2023-04-26 2023-08-08 上海大学 4-氟-7-氮杂吲哚的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012976A (en) * 1909-03-25 1911-12-26 Adolf Bordt Adding-machine.
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
BRPI0416852A (pt) * 2003-11-21 2007-02-27 Array Biopharma Inc inibidores da quinase akt
CA2711614A1 (en) * 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
DK2294065T3 (da) * 2008-01-22 2014-04-28 Vernalis R&D Ltd Indolyl-pyridonderivater med checkpoint kinase 1 inhibitorisk aktivitet
AR071717A1 (es) * 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
JP5677945B2 (ja) * 2008-06-11 2015-02-25 ジェネンテック， インコーポレイテッド ジアザカルバゾール及びその使用方法
KR20120055608A (ko) * 2009-08-06 2012-05-31 메르크 파텐트 게엠베하 신규한 이환 우레아 화합물
EP2571361A4 (en) * 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds

Also Published As

Publication number Publication date
EP2809670B1 (en) 2017-05-17
PL2809670T3 (pl) 2017-10-31
US10889582B2 (en) 2021-01-12
ES2637340T3 (es) 2017-10-11
CA2862940C (en) 2021-09-14
US20150011533A1 (en) 2015-01-08
BR112014018795A2 (pt) 2017-07-04
CN106866658A (zh) 2017-06-20
MX2014009112A (es) 2014-11-10
HUE035332T2 (en) 2018-05-02
US20210206762A1 (en) 2021-07-08
IL233595A0 (en) 2014-08-31
CA2862940A1 (en) 2013-08-08
JP6199316B2 (ja) 2017-09-20
IN2014DN06104A (en:Method) 2015-08-14
WO2013114113A1 (en) 2013-08-08
CN107011341A (zh) 2017-08-04
US10000481B2 (en) 2018-06-19
BR112014018795B1 (pt) 2020-09-29
EA201491376A1 (ru) 2015-01-30
GB201201566D0 (en) 2012-03-14
EP2809670A1 (en) 2014-12-10
AU2013213954A1 (en) 2014-08-07
JP2015505555A (ja) 2015-02-23
HK1200447A1 (en) 2015-08-07
CN104203948A (zh) 2014-12-10
PT2809670T (pt) 2017-08-23
DK2809670T3 (en) 2017-08-28
MX352927B (es) 2017-12-14
EA026657B1 (ru) 2017-05-31
CN106866658B (zh) 2021-04-27
AU2013213954B2 (en) 2016-02-25
IL233595B (en) 2018-05-31
CN111484493A (zh) 2020-08-04
NZ627361A (en) 2016-07-29
US20180362526A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
ZA201405070B (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
ZA201906379B (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
SMT201700539T1 (it) DERIVATI IMIDAZO[1,2-b]PIRIDAZINICI COME INIBITORI DI CHINASI
IL235819B (en) Derivatives of [(2-fluoro-3-amino)phenyl]carbonyl-pyrrolo [3,2-b]pyridin-3-yl and a method for their preparation
ZA201507874B (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
IL238493B (en) Amino-substituted imidazo[a–2,1]pyridinecarboxamides and their use
RS55388B1 (sr) Furo[3, 2 - b]piridin derivati kao tbk1 i ikk inhibitori
ZA201506182B (en) Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as ssao inhibitors
ZA201307511B (en) Pyrido [2,3-b] pyrazine derivatives and their therapeutical uses
IL232717A0 (en) 3-cyanoaryl-h1-pyrrolo[b-3,2]pyridine derivatives
EP2970278A4 (en) Pyrrolo [2,3] PYRIDINE KINASE INHIBITORS CDK9-
SG11201408816QA (en) 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
SG11201500883YA (en) 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS